← All trials
NCT05574439
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Oct 30, 2024
- Completion date
- Jun 1, 2026
- First posted
- Oct 10, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 170
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenCollaborator
- Karolinska InstituteCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenSponsor investigator
- University of CopenhagenStudy director
- University of LeedsCollaborator
- University of CopenhagenOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.